On Invalid Date, Genmab A (NASDAQ: GMAB) reported Q4 2023 earnings per share (EPS) of $0.15, up 27.19% year over year. Total Genmab A earnings for the quarter were $94.81 million. In the same quarter last year, Genmab A's earnings per share (EPS) was $0.11.
As of Q1 2024, Genmab A's earnings has grown -17.74% year over year. This is 69.59 percentage points lower than the US Biotechnology industry earnings growth rate of 51.85%. Genmab A's earnings in the past year totalled $633.48 million.
What is GMAB's earnings date?
Genmab A's earnings date is Invalid Date. Add GMAB to your watchlist to be reminded of GMAB's next earnings announcement.
What was GMAB's revenue last quarter?
On Invalid Date, Genmab A (NASDAQ: GMAB) reported Q4 2023 revenue of $693.04 million up 6.37% year over year. In the same quarter last year, Genmab A's revenue was $740.20 million.
What was GMAB's revenue growth in the past year?
As of Q1 2024, Genmab A's revenue has grown 16.77% year over year. This is 152.53 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Genmab A's revenue in the past year totalled $2.40 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.